Author:
Hatschek T.,Baldetorp L.,Carstensen J.,Håkansson L.,Möller T.,Nelsson B.,Termander B.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Gaver R C, Deeb G, Pittman K A, Issell B F, Mittelman A, Smyth R D: Disposition of orally administered [14C]-prednimustine in cancer patients.Cancer Chemother. Pharmacol.
11, 139–143 (1983).
2. Newell D R, Calvert A A H, Harrap K R, McElwain T J: Studies of the pharmacokinetics of chlorambucil and prednimustine in man.Br. J. Clin. Pharmacol.,15, 253–258 (1983).
3. Løber J, Mouridsen H T, Christiansen I E, Dombernowsky P, Mattsson H T, Rørth M: A phase III trial comparing prednimustine (Leo 1031) to chlorambucil plus prednisolone in advanced breast cancer.Cancer,52, 1570–1576 (1983).
4. Hiller E, Thiel E, Emmerich B et at. on behalf of the German-Austrian Lymphoma Study Group: Randomized study comparing Sterecyt (prednimustine) and chlorambucil + prednisolone in non-Hodgkin’s lymphoma of low grade malignancy, clinical stages III-IV. Presented at the 13th ESMO-congress in Lugano 1988.
5. Hryniuk W: The impact of dose intensity on the design of clinical trials.Semin. Oncol.,14, 65–74 (1987).